‘Legal’ psychedelic mushrooms actually contain illegal hallucinogens, study shows
WASHINGTON – A new study published Thursday finds that several mushroom candies, which are widely…
Category: Medicine
STAT+: Here come Medicare’s first negotiated drug prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
JD Vance’s rhetoric, and record, on the opioid epidemic
JD Vance says he’s grown all too accustomed to hearing a certain phrase when his…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
.jpg)
The biotech news stories you need to know today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more
Top of the morning to you, and a fine one it is, despite the gray…
Opinion: Real-time vital signs data: a hidden source of value in medical AI
If data represents the next gold rush for health care, a vast treasure trove of…
.jpg)
STAT+: Broad Institute, facing end of Microsoft cloud contract, shuffles data science leadership
The Broad Institute of MIT and Harvard is perhaps best known for the trailblazing work…
STAT+: Startup Q Bio raises $27 million to build its own full-body scanner
A prevention-focused co-founded by the head of a Stanford research lab is making an expensive…
Opinion: IRBs fail to assess trials’ scientific merit, putting participants at risk
Thousands of people volunteer for clinical research trials in the United States every year. They…
STAT+: Q&A: The new CEO of biotech’s top trade group on China, vaccines, and Trump
WASHINGTON — BIO’s new CEO John Crowley is making changes. He’s pivoting the biotechnology industry’s…
STAT+: Novartis hedges on when it might submit myelofibrosis drug for approval
LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the…
Physicians weigh in on potential impact of Trump’s ear wound: “It’s a matter of inches”
Four days after former president Donald Trump was shot in the ear at a rally…
Vaccination slashes risk of long Covid, says large study tracing cases through Delta and Omicron variants
Vaccination lowers the chance of developing long Covid, according to a large new study that…
Bone marrow donors needn’t be perfect match, study says, paving way for more equitable access
As a hematologist-oncologist in Miami, Mikkael Sekeres always hopes his patients will find a perfect…
STAT+: Elevance tumbles as health insurer warns Medicaid members are using more care
Wall Street’s reaction was swift Wednesday after Elevance Health said that the amount of care…
STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world
Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the…
STAT+: Gilead’s chief medical officer to leave as R&D efforts stall
Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker…
STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
It’s happy hour (for now) for Alnylam
Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and…
STAT+: A second Roche obesity drug shows promise in early studies
LONDON — Roche on Wednesday reported positive early data from another of the obesity drug…
STAT+: Data privacy startup raises $30 million, to ease health care providers’ regulatory burden
Federal guidance restricting hospital websites’ use of third-party trackers along with the proliferation of direct-to-consumer…
Opinion: Listen: Empathy should be the first response to people with vaccine injury, fears
For scientists and medical professionals well versed in the safety and effectiveness of vaccines, it…
As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them
Around the world, patients suddenly can’t find enough of the insulins made by companies they…
STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down
A clutch of headlines last week suggested the U.S. Senate had achieved a breakthrough in…
STAT+: Why clinical trials for digital therapeutics are getting more rigorous
Faced with widespread skepticism about the value of digital therapies, Swing Therapeutics in early 2022…
Opinion: OB-GYN board certification shouldn’t require traveling to Texas, a state hostile to abortion and abortion providers
Taking the oral examination is the final step in becoming a board-certified obstetrician and gynecologist…
Long Covid is more prevalent among Americans with disabilities, new CDC data show
The Centers for Disease Control and Prevention just released a trove of data on Americans…
Sen. Menendez’s conviction may cost pharma a key ally in Congress
A New York jury on Tuesday found Sen. Bob Menendez guilty on 16 counts for…
STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund
Cardurion Pharmaceuticals, a startup that launched seven years ago with shelved cardiovascular drug candidates from…
STAT+: Applesauce lead contamination could not have been prevented, top FDA officials says
CHICAGO – The FDA’s top food regulator contended Tuesday that the agency could not have…
STAT+: UnitedHealth CEO concedes company was ‘over-optimistic’ about Change cyberattack recovery
UnitedHealth Group’s CEO said Tuesday that his team was “over-optimistic” about the pace at which…
USDA maintains bird flu can be eliminated from dairy cows, even as doubts mount among experts
Facing increasing doubts that the U.S. can control the outbreak of avian influenza among dairy…
Addressing the “postpartum cliff” may be as simple as a sending few text messages
Most pregnant people are in regular touch with their maternity care providers over the course…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
Opinion: Addressing the dual epidemics of hepatitis C and opioid use
Hepatitis C and opioid use disorder are both chronic but treatable conditions. Yet many Americans…
STAT+: A cancer care startup is making a new bet with payers and providers: only pay if it works
A cancer care navigation startup has raised $95 million from prominent tech investors to help…
At an Iowa county fair, a tradition carries on despite bird flu anxiety in the dairy barn
DECORAH, Iowa — It was livestock check-in day at the Winneshiek County Fair, and the…
Opinion: Why aren’t philanthropists stepping up to support nursing education?
Michael Bloomberg’s donation of $1 billion to Johns Hopkins University to support medical education goes…
What to know about Trump VP pick J.D. Vance’s health care views and investments
WASHINGTON — Sen. J.D. Vance, who was tapped to be former President Trump’s running mate…
Q&A: Why more info can lead some women to prefer delaying first mammogram
The messaging around mammography often doesn’t go beyond this simple three-word refrain: screening saves lives….
Vertex sues U.S. government over access to fertility support services for Casgevy patients
One of the makers of the Casgevy — the world’s first CRISPR-based medicine — filed a lawsuit…
STAT+: Medicare pay proposals are good news for health tech, bad news for docs
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Early data from Lexeo’s gene therapy for rare heart disease shows promise
Lexeo Therapeutics said Monday that a gene therapy designed to prevent fatal cardiac complications of…
STAT+: The effort to reform physician pay is set to pit primary care docs against highly paid specialists
WASHINGTON — There’s been a long lull in fighting between primary care and specialty doctors…
Bird flu snapshot: As the number of infected dairy herds mount, so too does pessimism about driving H5N1 out of cows
Bird flu snapshot: This is the latest installment in a series of regular updates on…
Opinion: Medicare drug pricing rules will delay access to promising therapies
Medicare’s new guidelines cover how it will conduct the drug price negotiations authorized by the…